The Future of Autoinjectors
October 7, 2025Innovations in Drug Delivery Manufacturing
The future of autoinjectors is about more than new devices. It’s about giving patients confidence and control in their treatment. Autoinjectors, originally designed for the US Military in the 1950s, have become an everyday lifeline.
Inventors were issued their US Patent in 1977, and the FDA approved the EpiPen for commercial use in 1987.
With faster delivery, accurate dosing, and the convenience of use at home or on the go, it’s no surprise autoinjectors have become so widely used.
Another driver for autoinjector use is that biologics and specialty drugs continue to grow more common. The global market was estimated at USD 9.2 billion in 2024 and is projected to grow at ~15% per year, more than doubling by 2030.
Meeting that demand takes more than a redesigned device. The drug must remain stable, manufacturing must safeguard sterility at every step, and the product must meet all regulatory standards.
CDMOs, like Pyramid Pharma Services, help pharma companies align all three, ensuring that autoinjectors reach patients safely and effectively.
Why Autoinjectors Matter
At Pyramid, a great deal of our formulation work focuses on ensuring drug products remain stable and effective when delivered through autoinjectors. That stability is what makes these devices so valuable to patients managing their conditions.
For patients, the benefits of autoinjectors are clear:
- Ease of use: simple operation with minimal instructions
- Improved safety: fewer dosing errors and lower risk of needle-stick injuries
- Convenience: the ability to manage treatment at home or on the road, without relying on clinic visits
These advantages translate into stronger adherence, better outcomes, and broader adoption. A review of nearly 3,000 injections showed a failure rate of only 0.40% (PubMed Central), proving their reliability.
By pairing formulation expertise with device integration, Pyramid helps ensure therapies work in the lab and perform consistently for patients.
What’s Next in Autoinjector Design
Pyramid’s aseptic syringe filling capabilities are already aligned with the future of autoinjectors in mind. Since most autoinjectors rely on prefilled syringes, ensuring sterility and precision in this step is essential.
With that foundation in place, the industry can pursue new designs such as:
- Connected features that track use and share data with digital health tools
- Smaller, lighter devices that fit into daily routines more comfortably
- User-friendly designs that help older adults and patients with dexterity or vision challenges
- Sustainable approaches such as recyclable materials and, in some cases, exploring reusable formats to reduce waste
Design innovation means little without reliable fill-finish and lyophilization expertise behind it. Pyramid integrates both, making it possible for pharma companies to deliver patient-ready formats that meet future market demands.
Pyramid’s Perspective
With autoinjectors becoming a preferred option for patient-friendly delivery, manufacturers are turning to partners that are both experienced and flexible. Dirk Lange, CEO of Pyramid Pharma Services, explains in Pharmaceutical Outsourcing:
“We are seeing increased demand for our drug product (DP) development and manufacturing services across biologics, small molecules and specifically novel modalities such as oligonucleotides, where Pyramid offers differentiated capabilities and years of experience.”
That demand also includes the ability to scale. Pyramid’s commercial teams guide products through FDA and international approvals and provide packaging and labeling to prepare therapies for market.
With experience across North America, Europe, Japan, and Australia, Pyramid ensures clients have confidence that their autoinjector programs will move from the lab to global patients without interruption.
The Role of Partnerships
Pyramid Pharma Services shows why CDMOs are indispensable for autoinjector success. Developing these therapies requires seamless integration of formulation, aseptic manufacturing, and quality control. Few pharma companies can manage all of that internally.
By combining in-house quality control and microbiology labs with commercial-scale aseptic manufacturing, Pyramid reduces risk and accelerates timelines. These capabilities allow pharma companies to move from early-stage development to commercial supply without disruption.
Shaping the Future of Autoinjectors
Autoinjectors are becoming central to how patients receive and manage treatment. Their success depends on device innovation and strong partnerships that support formulation, fill-finish, and global commercialization.
Pyramid Pharma Services brings these capabilities together. By combining scientific expertise with manufacturing strength and regulatory experience, Pyramid ensures that therapies reach patients in the formats they need today and in the future.
About Pyramid Pharma Services
Pyramid Pharma Services is a full-service CDMO with deep expertise in parenteral biologics. From early development through commercial-scale manufacturing, Pyramid provides the technical, regulatory, and scientific capabilities needed to prepare complex therapies in safe, patient-ready formats. By combining expertise with flexible partnerships, we help pharma and biotech companies advance therapies quickly, reliably, and to the highest quality standards.